Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
Open Access
- 26 August 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 99 (6), 862-867
- https://doi.org/10.1038/sj.bjc.6604628
Abstract
Advanced biliary tract carcinomas (BTCs) are often diagnosed at an advanced/metastatic stage and have a poor prognosis. The combination of gemcitabine and oxaliplatin (GEMOX) has shown promising activity in this setting. This international phase II study evaluated the efficacy and safety of GEMOX as first-line therapy in patients with advanced BTCs. Eligible patients with previously untreated locally advanced or metastatic BTC received gemcitabine 1000 mg m−2 (day 1) and oxaliplatin 100 mg m−2 (day 2), every 2 weeks. Seventy patients were enroled; 72.9% had metastatic disease. Sixty-seven patients were treated. There were 10 confirmed partial responses (14.9%; 95% confidence interval (CI), 7.4–25.7%) in the treated population (RECIST). Twenty-four patients (35.8 %) had stable disease. The objective response rate was 20.5% in patients with non-gallbladder cancers (9/44 patients) and 4.3% in patients with gallbladder cancers (1/23). Median overall survival for the intent-to-treat population was 8.8 months (95% CI, 6.9–11.1%) and progression-free survival was 3.4 months (95% CI, 2.5–4.6%). Grade 3/4 toxicities included thrombocytopenia (14.9% of patients), alanine aminotransferase elevation (13.4%), anaemia (10.4%), neutropenia (11.9%) and pain (11.9%). In this study, GEMOX demonstrated activity in non-gallbladder carcinoma, but poor activity in gallbladder carcinoma. GEMOX is well tolerated in advanced BTCs.Keywords
This publication has 24 references indexed in Scilit:
- Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 StudyBritish Journal of Cancer, 2009
- Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder CancerDigestive Diseases and Sciences, 2007
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancerBritish Journal of Cancer, 2006
- Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinomaCancer, 2004
- Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR studyAnnals of Oncology, 2004
- Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trialsSeminars in Oncology, 2002
- Epidemiology and Molecular Pathology of Gallbladder CancerCA: A Cancer Journal for Clinicians, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Biliary Tract CancersNew England Journal of Medicine, 1999